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ARTICLE

OPEN

Utility of the JAX Clinical Knowledgebase in capture and
assessment of complex genomic cancer data
Sara E. Patterson1, Cara M. Statz1, Taofei Yin1 and Susan M. Mockus1
Cancer genomic data is continually growing in complexity, necessitating improved methods for data capture and analysis. Tumors
often contain multiple therapeutically relevant alterations, and co-occurring alterations may have a different inﬂuence on
therapeutic response compared to if those alterations were present alone. One clinically important example of this is the existence
of a resistance conferring alteration in combination with a therapeutic sensitizing mutation. The JAX Clinical Knowledgebase (JAXCKB) (https://ckb.jax.org/) has incorporated the concept of the complex molecular proﬁle, which enables association of therapeutic
efﬁcacy data with multiple genomic alterations simultaneously. This provides a mechanism for rapid and accurate assessment of
complex cancer-related data, potentially aiding in streamlined clinical decision making. Using the JAX-CKB, we demonstrate the
utility of associating data with complex proﬁles comprising ALK fusions with another variant, which have differing impacts on
sensitivity to various ALK inhibitors depending on context.
npj Precision Oncology (2019)3:2 ; https://doi.org/10.1038/s41698-018-0073-y

INTRODUCTION
Tumors are genomically complex, often arising as the result of a
combination of alterations that ultimately lead to uncontrolled
cellular proliferation. Once formed, tumors continue to evolve,
acquiring additional alterations that contribute to temporal and
spatial tumor heterogeneity and which potentially enable the
tumor to evade immune response or therapeutic intervention.1–3
Historically, precision oncology has been approached through
targeting a single driver alteration, potentially in the presence of
other relevant mutations. As knowledge of tumor biology
continues to grow, it becomes increasingly apparent that
alterations often work in concert to affect pathway regulation
and therapeutic efﬁcacy highlighting the need for new targeted
therapies and combination therapies that target multiple alterations simultaneously.2,4–7 For example, in lung cancer, the notion
of the single driver alteration has been dispelled by studies
demonstrating multiple co-occurring driver alterations in patients
with EGFR-mutant non-small cell lung cancer, including mutations
in PIK3CA or CTNNB1.8–10
One important aspect of tumor biology is the acquisition of
mutations that confer therapeutic resistance, which often arise in
the context of a therapy sensitizing mutation, and frequently
occur following intervention with targeted therapies.4,11 One wellknown example of this is the EGFR T790M mutation, which
commonly occurs in lung cancer patients with EGFR-inhibitor
sensitizing mutations following treatment with EGFR tyrosine
kinase inhibitors and renders ﬁrst and second-generation inhibitors ineffective.8,12–14 Resistance to EGFR inhibitors in the context
of an EGFR activating mutation can also occur through the
acquisition of a number of other types of alterations, such as MET
ampliﬁcation or a CCDC6-RET fusion.15–17 Secondary mutations
can also confer therapeutic resistance via other mechanisms, such
as resistance to PARP inhibitors in patients with BRCA1 frameshift
mutations via acquisition of mutations that restore the BRCA1
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open reading frame, termed reversion mutations.18 Knowledge
surrounding the varied types of resistance mechanisms that can
arise, as well as ways to circumvent therapeutic resistance, is key
to effective patient treatment.
Therapeutic resistance is exempliﬁed by the acquisition of
speciﬁc alterations in the context of ALK fusions following
treatment with ALK inhibitors. ALK is a receptor protein tyrosine
kinase that belongs to the insulin receptor superfamily of protein
tyrosine kinases, and was originally identiﬁed as a component of a
fusion protein commonly found in anaplastic large cell lymphomas.19,20 Upon ligand binding, ALK activates downstream signaling through several pathways, including RAS/RAF/MEK/ERK, JAK/
STAT, PI3K, and PLC, which play a role in regulation of cell
proliferation and survival.19,20 Fusions between ALK and various
partners, commonly EML4 in non-small cell lung cancer and NPM1
in anaplastic large cell lymphoma, lead to constitutive activation
of downstream signaling and function as oncogenic drivers.19,20
Because of this, ALK inhibitors have been developed to target
these fusions and several have obtained FDA approval.21 However,
while initially successful, ALK inhibitor therapy ultimately fails for
many patients, as various resistance mechanisms emerge to
circumvent therapeutic efﬁcacy. These resistance mechanisms
include ALK missense mutations, as well as copy number
alterations, or mutations in alternate pathways that activate
bypass signaling.21–23
Capturing and visualizing the data related to these complex
scenarios is paramount to advancing our understanding of tumor
biology and precision oncology. However, data regarding efﬁcacy
of targeted therapies are currently primarily captured as they
relate to a single alteration, and other tumor-related alterations
may be disregarded. As a result, gleaning insight into the
relationship between more than one potentially important
alterations in a tumor and therapeutic efﬁcacy can prove
challenging. To address this, we have incorporated the concept
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curation methodology is available in the help section on the ckb.
jax.org website.
Rather than considering each variant individually, the association of data in the JAX-CKB with complex molecular proﬁles
enables a user to quickly assess the relationship between multiple
tumor alterations and their compound impact on therapeutic
efﬁcacy. In this way, interpretation of somatic variants can be done
on a more holistic level, potentially improving the clinical
decision-making process. Here, we present the utility of the JAXCKB in capturing and analyzing data related to complex molecular
proﬁles, with a speciﬁc emphasis on the ability to quickly visualize
and analyze data related to therapy resistance.

Fig. 1 The JAX-CKB complex molecular proﬁle. a Structure of the
relationship between the complex molecular proﬁle (top) and
therapy response, via the molecular proﬁle response. b Example of a
molecular proﬁle response associated with a complex proﬁle. This
complex molecular proﬁle comprises two alterations: EGFR
E746_A750del and MET ampliﬁcation, which was demonstrated in
a clinical study (evidence source) to be resistant (response type) to
Osimertinib (therapy) in a lung adenocarcinoma (tumor type)
patient

of a “complex molecular proﬁle” into the JAX Clinical Knowledgebase (JAX-CKB), which enables us to relate evidence of therapeutic
efﬁcacy to a collection of molecular changes, or molecular proﬁle,
which can include single nucleotide variations (SNVs), copy
number variations (CNVs), fusions, and/or expression level
changes. Thus, the complex molecular proﬁle provides opportunity for a more accurate representation of the genomic conditions
inﬂuencing therapeutic response as they are reported in the
literature, and reduces the potential for erroneous interpretation.
The JAX-CKB is a relational knowledgebase that incorporates
integrated data related to cancer-associated genomic variants,
therapeutic efﬁcacy, and clinical trials, which is populated largely
by manual curation of data from the scientiﬁc literature and
provides a powerful tool for interpretation of genomic data in
cancer.24 This differs from a genomic repository or genomic
database, such as COSMIC or cBioPortal, that focuses on
warehousing genomic data from patient clinical samples, which
can be in turn used for large scale analyses of genomic variation in
cancer.25–27 A knowledgebase, such as the JAX-CKB, can be used
as a complement to these genomic repositories, as a platform for
interpretation of those variants found in patient samples. The
interpretations and in-depth connections provided in the JAX-CKB
are primarily sourced from the published literature, and relevant
npj Precision Oncology (2019) 2

RESULTS
Data relationships in the JAX-CKB
To capture data related to multiple alterations simultaneously, we
have designed the JAX-CKB to include a concept we have termed
the ‘molecular proﬁle’. Molecular proﬁles can contain one or more
gene variants, including any combination of single nucleotide
variants, insertions, deletions, duplications, copy number variants,
and/or expression changes. Naming convention for single
nucleotide variants, small insertions or deletions, and duplications
follows Human Genome Variation Society (HGVS) compliant
nomenclature, to reduce ambiguity. The JAX-CKB also incorporates higher order variants to accommodate unspeciﬁed variants,
such as EGFR mutant, EGFR act mut (for EGFR activating mutation),
and EGFR exon 19 deletion. These higher order, or “category”
variants enable curation of data where the speciﬁc alteration
present is not identiﬁed.
Complex molecular proﬁles can contain variants from multiple
genes, such ‘KRAS G12D + PTEN dec exp + TP53 R306*’, where
PTEN dec exp refers to decreased expression of PTEN. These
molecular proﬁles are linked to structured free-text efﬁcacy
evidence annotations, curated from the published literature, via
the ‘molecular proﬁle response’. The molecular proﬁle response
comprises the relationship between the molecular proﬁle, a
therapy, the relevant indication or tumor type (assigned a disease
ontology term and backed by a unique disease ontology ID28,29),
the evidence source (also termed “approval status” in the JAX-CKB
knowledgebase), and response type, incorporating controlled
vocabularies for query retrieval (Fig. 1). The evidence source refers
to the type of study from which the data was derived, which
includes terms related to preclinical and clinical data. The
response type refers to the sensitivity or resistance associated
with a given molecular proﬁle/therapy/indication combination.
We have also incorporated the terms “conﬂicting” to handle cases
where studies exist with conﬂicting ﬁndings, and “unknown” to
handle cases where there is no clear response type associated
with the curated ﬁnding(s). For example, the term “unknown” is
used for annotations where therapeutic efﬁcacy results are
reported, but the signiﬁcance as it relates to the associated
molecular proﬁle is unclear. Evidence annotations assigned the
response type of “unknown” were excluded from analysis.
Overall data distribution
To gain perspective on the overall landscape of efﬁcacy data
curated into the JAX-CKB, we performed analysis on evidence
curated to single or complex molecular proﬁles. Analysis of
efﬁcacy evidence in the JAX-CKB demonstrated that 31% of 9271
curated evidence lines are associated with complex molecular
proﬁles (Fig. 2a). Of those, 87.3% of evidence lines are based on
preclinical studies (represented by the sum of the blue portions of
the bars in Figs. 2b), and 12.7% from clinical studies or clinical trial
data (represented by the sum of the orange portions of the bars in
Fig. 2b). Of the total efﬁcacy evidence lines associated with
complex molecular proﬁles, 55.1% are associated with a positive
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Fig. 2 Analysis of efﬁcacy evidence annotations associated with complex molecular proﬁles in the JAX-CKB. a Percent of efﬁcacy evidence
associated with complex (orange) or single variant (blue) proﬁles. b Percent of efﬁcacy evidence annotations associated with complex
molecular proﬁles. Percent of efﬁcacy evidence annotations associated with a positive therapeutic response represented by the left bar
(55.1%), and annotations associated with a negative response represented by the right bar (44.9%). Data are further divided as they
correspond to preclinical (blue) or clinical (orange) data

Fig. 3 Efﬁcacy evidence in the JAX-CKB corresponding to complex proﬁles containing ALK fusions. a Response of ALK variants (top) within
EML4-ALK or NPM1-ALK fusions to ALK inhibitors (left). Green = evidence corresponding to sensitivity, red = evidence corresponding to
resistance, orange = conﬂicting evidence, gray = no available evidence in the JAX-CKB. b Percentage of efﬁcacy evidence annotations for
complex proﬁles comprising EML4-ALK plus 1 variant or NPM1-ALK plus 1 variant associated with negative or positive response. c Location of
variants in EML4-ALK (top) or NPM1-ALK (bottom) associated with negative response efﬁcacy evidence in the JAX-CKB (modiﬁed from
cBioPortal MutationMapper tool25,26). Only the ALK portion of the fusion is displayed. d Example demonstrating the structure of complex data
from a case study curated in CKB, with varied therapies, response types, and molecular proﬁles over a treatment course

response type (those that indicate a positive association between
the molecular proﬁle and therapeutic response), and 44.9% are
associated with a negative response type (Fig. 2b).
Evidence related to ALK fusion containing complex proﬁles
As a proof of concept on the utility of capturing data related to
complex proﬁles, we examined data in the JAX-CKB that relates to
complex molecular proﬁles comprising ALK fusions in combination with additional ALK variants. Secondary mutations in ALK
often occur in tumors with activating ALK fusions following
treatment with ALK-targeted therapies and may confer resistance
to one or more therapies. Using the JAX-CKB, we analyzed the
efﬁcacy data related to response of several ALK mutations to
various ALK inhibitors, approved or in clinical development, in the
context of EML4-ALK or NPM1-ALK. Analysis of data corresponding
to the ALK inhibitor Alectinib demonstrated that several ALK
mutations result in a negative response in the context of NPM1ALK but are sensitive in the context of EML4-ALK (T1151M, F1174L,
R1192P, E1210K, G1269A) (Fig. 3a). Efﬁcacy data for EML4-ALK with
Published in partnership with The Hormel Institute, University of Minnesota

ALK L1196M, I1171S, or I1171T, or L1198F were conﬂicting, with
data corresponding to both sensitivity and decreased sensitivity to
Alectinib. Several mutations also demonstrated differential sensitivity to the ALK inhibitors Brigatinib, Ceritinib, Crizotinib, or
Lorlatinib depending on whether they were present in EML4-ALK
or NPM1-ALK (Fig. 3a). Complex proﬁles containing NPM1-ALK
plus an additional ALK variant were more likely to be associated
with insensitivity to ALK inhibitors, with 73.3% of the curated
efﬁcacy evidence lines corresponding to a negative response,
whereas 41.1% of EML4-ALK complex proﬁles were associated
with negative response data.
Comparison of the speciﬁc ALK complex proﬁles curated with
negative ALK inhibitor response data demonstrated a 57% overlap
between variants curated into the JAX-CKB that are associated
with negative response data in EML4-ALK and NPM1-ALK, with
19% of variants curated unique to NPM1-ALK, and 24% unique to
EML4-ALK (Fig. 3c).
The JAX-CKB also has the capability of capturing data related to
more complex scenarios, including data corresponding to
therapeutic response in the context of tertiary mutations,
npj Precision Oncology (2019) 2

S.E. Patterson et al.

4
occurring in tandem with ALK fusions and secondary ALK
mutations. This is exempliﬁed by the representation of data from
a clinical case study30 as captured in the JAX-CKB (Fig. 3d). In this
case study, a non-small cell lung cancer patient harboring EML4ALK demonstrated an initial response to treatment with Crizotinib,
but subsequently demonstrated resistance following the acquisition of the ALK C1156Y mutation (top left). This patient was then
treated with Lorlatinib, with a response, but progressed following
acquisition of the ALK L1198F mutation (top right). The patient
was then treated again with Crizotinib and demonstrated a
response (bottom right).
DISCUSSION
Complex alterations are common in tumors; however, data related
to therapeutic efﬁcacy in these contexts are difﬁcult to obtain as
the majority of cancer-related efﬁcacy data are represented in the
context of a single relevant alteration. Moreover, therapeutic
decision-making often focuses, when present, on a single known
actionable target alteration, which may relate to poor activity of
single-agent targeted therapeutics. Single agent therapies have
demonstrated efﬁcacy with some well-known driver alterations,
such as Vemurafenib with BRAF V600E mutations in melanoma,31
Erlotinib with EGFR exon 19 deletions in non-small cell lung
cancer,32 or Imatinib with BCR-ABL1 fusions in chronic myeloid
leukemia,33 leading to FDA approval. However, while initially
successful, this efﬁcacy is often short-lived as various resistance
mechanisms can occur that activate bypass or parallel pathway
signaling, resulting in decreased activity of the targeted therapy.34–38 Techniques for non-invasive patient biopsy and detection of mutations present in small cell numbers are constantly
improving, allowing physicians to tailor patient treatment accordingly as resistance to targeted therapies develops. However,
interpretation of these complex scenarios is non-trivial. Visualization into the various mechanisms potentially impacting therapeutic efﬁcacy, represented as relevant combinations, would provide
value for clinical decision making or research purposes. Here, we
have demonstrated the utility of capturing therapeutic data
related to several relevant alterations, which we have enabled in
the JAX-CKB via the concept of a “complex molecular proﬁle”.
Efﬁcacy data curated to complex molecular proﬁles represents a
signiﬁcant and growing area of the JAX-CKB, reﬂecting the
importance of these types of data.
The response to therapy in oncology is impacted by several
factors, including the speciﬁc combination of alterations present
in the tumor. In the case of ALK alterations occurring in the
context of an ALK fusion, it is tempting to categorize them as
wholly resistant or sensitive to speciﬁc ALK-targeted therapies.
However, as represented by our analysis, a therapy may be
effective in the presence of a given variant when found in EML4ALK, but not in NPM1-ALK, highlighting the importance of
considering the entire proﬁle rather than a single alteration. One
limitation to this analysis is the relative impact of the tumor type
on the response to a therapy. EML4-ALK is commonly associated
with non-small cell lung cancer; NPM1-ALK is most frequent in
anaplastic large cell lymphoma. While we did not break down the
analysis by tumor type, the majority (86%) of the analyzed data
related to preclinical studies using transformed cell lines,
expressing either NPM1-ALK-based constructs or EML4-ALKbased constructs, thus effectively normalizing the analysis.
An additional point of consideration is the existence of several
distinct EML4-ALK variants, with differential stability and domains
and differential response to ALK inhibitors, adding an additional
layer of complexity.39,40 Shorter EML4-ALK variants have been
demonstrated to have higher stability and are less responsive to
ALK inhibitors,40 which may in part be reﬂected in the conﬂicting
results seen in studies looking at the sensitivity of different ALK
mutations in EML4-ALK to ALK inhibitors. For example, the
npj Precision Oncology (2019) 2

evidence for sensitivity of I1171S to Ceritinib in CKB comes from
a study that expressed this mutation in variant 1 of EML4-ALK,22
where the study demonstrating resistance used a construct based
on the shorter EML4-ALK variant 3.41 Also, while all known EML4ALK variants include the ALK protein kinase domain as well as the
EML4 transactivation domain, the breakpoint and domain
composition of EML4 is variable. EML4-ALK variants differ in
respect to inclusion of EML4 HELP and/or TAPE domains, which
may play a role in response to therapy.42 The identity of the ALK
fusion partner has also demonstrated role in the sensitivity of ALK
inhibitors,39 and NPM1-ALK has been shown to be generally less
sensitive to ALK inhibition compared to EML4-ALK, supporting the
ﬁndings reported here.
Of the ALK inhibitors analyzed, ﬁve are FDA-approved for use in
patients: Alectinib (Alecensa), Crizotinib (Xalkori), Ceritinib (Zykadia), Brigatinib (Alunbrig), and Lorlatinib (Lorbrena); while the
others are in various stages of clinical development. Outside of
Crizotinib (Xalkori), the ALK inhibitors analyzed are second or
third-generation inhibitors, designed to overcome therapeutic
resistance. Patients treated with next-generation ALK inhibitors
following acquisition of resistant mutations may develop additional tertiary mutations that confer resistance to these newer
drugs as well, or potentially resensitize patients to ﬁrst-generation
ALK inhibitors.30 The JAX-CKB is designed to capture and display
these types of data, potentially aiding in interpretation of complex
scenarios. Additionally, the availability of a system such as the JAXCKB that enables the user to quickly assess mutations that are
potentially resistant to targeted therapies, such as speciﬁc ALK
alterations in the context of an ALK fusion, could potentially aid in
clinical trial design and analysis, as patients could be stratiﬁed by
presence or absence of potentially resistant variants. As data
around cancer-related genomic alterations and therapeutic
response grows in complexity, the JAX-CKB, through the complex
molecular proﬁle, has the capability of structuring those data in
meaningful and accurate ways, potentially facilitating more
accurate patient-speciﬁc therapy decisions.
METHODS
Database
The JAX-CKB is a relational database that houses integrated knowledge
related to genomic variants and targeted therapeutics in oncology. Details
related to the overall structure and relationships within the JAX-CKB
database have been published previously.24 Analysis was performed using
version 1.22.2 of the JAX-CKB. The JAX-CKB can be accessed at: https://ckb.
jax.org. Curation methodology for data in the JAX-CKB is available in the
‘Help’ section of the website.

Analysis
Data in the JAX-CKB [accessed on 12/07/2017] was queried to obtain
curated efﬁcacy evidence lines, which are free-text annotations summarizing ﬁndings from published literature related to therapeutic efﬁcacy,
corresponding to single or complex molecular proﬁles. For analyses of the
overall distribution of data in the database, both publicly available and
commercially available JAX-CKB content was used for larger sample size.
For ALK related efﬁcacy data, the JAX-CKB was queried to retrieve 362
efﬁcacy evidence lines corresponding to complex molecular proﬁles
containing an ALK fusion and additional variants, which was further
divided on proﬁles containing the variant EML4-ALK or NPM1-ALK plus an
additional ALK variant for analysis. Data was collated and sorted based on
response type, and/or efﬁcacy evidence study source. Data corresponding
to positive response type are those molecular proﬁle responses that are
assigned the response type of: ‘sensitive’ or ‘sensitive-predicted’; data
corresponding to negative response type are those that are assigned the
response type of ‘resistant’, ‘resistant-predicted’, ‘decreased response’, or
‘no beneﬁt’. When noted, data was divided by tumor type, with data
associated with the tumor type “Advanced Solid Tumor” corresponding to
unspeciﬁed tumor types or transformed cell lines. Data was also collated
by evidence source into preclinical categories (associated with ‘preclinical’,
‘preclinical-cell culture’, ‘preclinical-PDX’, ‘preclinical-cell line xenograft’,
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‘preclinical-PDX and cell culture’ terms), or clinical (associated with ‘Phase
I’, ‘Phase II’, ‘Phase III’, ‘Clinical Study’, or ‘FDA Approved’ terms). Analysis on
data corresponding to the efﬁcacy of speciﬁc drugs in the context of EML4ALK or NPM1-ALK plus a variant were restricted to those variants with
curated data for both fusions, and drugs in clinical development or FDA
approved.

DATA AVAILABILITY
Data used for analysis corresponding to ALK related content for this manuscript is
available at: https://ckb.jax.org/. The efﬁcacy evidence annotations used for analyses
of overall distribution of data for Fig. 2 are from the full JAX-CKB database, which
includes both publicly available content (those related to the 86 genes displayed
publicly at the time of analysis) as well as data available in the commercial version of
the JAX-CKB, which are not available publicly. However, analyses of public content
only are consistent with the full JAX-CKB content.
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